Clinical Trials Browser

Interventional × Taxes × Dermatologic × Clear all

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT06483555 2026-04-01

PANGEA

Phase 1/2 Recruiting

104 enrolled

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Phase 1/2 Active not recruiting

296 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04731467 2024-12-27

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Phase 1/2 Completed

79 enrolled

DermatologicEndocrineGastrointestinalGynecologicHead & NeckThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Phase 1 Completed

43 enrolled

DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

NCT02158520 2020-01-21

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

24 enrolled 10 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT00404235 2018-10-16

Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Completed

76 enrolled 10 charts

Dermatologic

Melanoma

NCT00626405 2018-05-01

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

95 enrolled 8 charts

Dermatologic

Melanoma

NCT00833807 2015-11-26

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Phase 1 Completed

30 enrolled

Dermatologic

Melanoma

NCT00110019 2015-10-19

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 3 Completed

823 enrolled 9 charts

Dermatologic

Melanoma

NCT00081042 2013-12-19

ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

Phase 2 Completed

Dermatologic

Melanoma

NCT00255762 2013-10-28

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Completed

47 enrolled

Dermatologic

Melanoma

NCT00288041 2013-03-05

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Phase 2 Completed

36 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT00970996 2013-01-03

BCAA

Phase 1 Completed

10 enrolled

Dermatologic

Melanoma

Clinical Trials

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

PANGEA

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

BCAA